NFL Biosciences SAS
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding… Read more
NFL Biosciences SAS (ALNFL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: 0.030x
Based on the latest financial reports, NFL Biosciences SAS (ALNFL) has a cash flow conversion efficiency ratio of 0.030x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€57.51K) by net assets (€1.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NFL Biosciences SAS - Cash Flow Conversion Efficiency Trend (2020–2022)
This chart illustrates how NFL Biosciences SAS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
NFL Biosciences SAS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NFL Biosciences SAS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dala Energi AB
ST:DE
|
0.011x |
|
I-Scream Edu Co.Ltd
KQ:289010
|
0.073x |
|
Elbit Imaging Ltd
PINK:EMITF
|
-0.016x |
|
Bicycle Therapeutics Ltd
NASDAQ:BCYC
|
-0.115x |
|
PPK Group Ltd
AU:PPK
|
-0.034x |
|
UOB Kay Hian Securities (Thailand) Public Company Limited
BK:UOBKH
|
0.148x |
|
va-Q-tec AG
PINK:VAQTF
|
0.065x |
|
Gia Lai Electricity JSC
VN:GEG
|
0.076x |
Annual Cash Flow Conversion Efficiency for NFL Biosciences SAS (2020–2022)
The table below shows the annual cash flow conversion efficiency of NFL Biosciences SAS from 2020 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | €844.00K | €104.89K | 0.124x | +369.60% |
| 2021-12-31 | €3.29 Million | €87.00K | 0.026x | -95.27% |
| 2020-12-31 | €150.03K | €83.91K | 0.559x | -- |